Advertisement

Topics

KOL Perceptions of Ustekinumab Data Presented at ACR 2017 [Report Updated: 26062018] Prices from USD $2500

08:57 EDT 16 Oct 2018 | BioPortfolio Report Blog

KOL Perceptions of Ustekinumab Data Presented at ACR 2017


Summary


This KOL Insight briefing focuses on perceptions of Ustekinumab Data Presented at ACR 2017.


The briefing includes analysis of KOL opinion on the following topic areas

Perception of ustekinumab's Phase II efficacy data in SLE

Views on ustekinumab demonstrating significant efficacy at Week 24 in SLE

Ustekinumab's Phase II CLASI data in SLE

Ustekinumab's Phase II safety data in SLE

Impact of ustekinumab data in other indications on opinion of ustekinumab in SLE

Endpoints used in the Phase II ustekinumab trial in SLE

Anticipated future use of ustekinumab in SLE

Ideal additional endpoints or data for future ustekinumab trials in lupus


Key Highlights


Most KOLs had a positive opinion of ustekinumab's efficacy in SLE and highlighted that it appears to have a better response rate vs. belimumab

KOLs were broadly impressed with ustekinumab's CLASI data, and expect it to encourage ustekinumab uptake in lupus skin manifestations

Most KOLs had a positive view of ustekinumab's safety, but concerns were raised regarding the small patient population in the Phase II trial.


Scope


The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders KOLs

In total, we conducted interviews with 14 KOLs: Seven Europebased seven USbased

Interviews performed in December 2017.


Reasons to buy


Combines Qualitative semiquantitative insight from key opinion leaders on "Ustekinumab Data Presented at ACR 2017"

Includes insight recommendations from our diseasespecific healthcare analysts

Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of Lupus

Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Original Article: KOL Perceptions of Ustekinumab Data Presented at ACR 2017 [Report Updated: 26062018] Prices from USD $2500

NEXT ARTICLE

More From BioPortfolio on "KOL Perceptions of Ustekinumab Data Presented at ACR 2017 [Report Updated: 26062018] Prices from USD $2500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Lupus
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...